Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer

Urology

Volumn 62, Issue 5, 2003, Pages 866-871

  Khan, Masood A ^a   Partin, Alan W ^a,b   Mangold, Leslie A ^a   Epstein, Jonathan I ^a   Walsh, Patrick C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DATA ANALYSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PELVIS LYMPHADENECTOMY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK ASSESSMENT; SCORING SYSTEM; SEMINAL VESICLE; SURVIVAL RATE;

EID: 0242412469     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00674-5     Document Type: Article

References (16)

1. Partin A.W., Yoo J.K., Carter H.B., et al. The use of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 150:1993;110-114.
2. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 58:2001;843-848.
3. Carter H.B., Coffey D.S. Prostate cancer the magnitude of the problem in the United States. Coffey D.S., Resnick M.I., Dorr F.A., et al. A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. 1988;1-7 Plenum Press, New York.
4. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer a multi-institutional update. JAMA. 277:1997;1445-1451.
5. Blute M.L., Bergstralh E.J., Partin A.W., et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 164:2000;1591-1595.
6. Narayan P., Gajendran V., Taylor S.P., et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology. 46:1995;205-212.
7. Tewari A., Narayan P. Novel staging tool for localized prostate cancer a pilot study using genetic adaptive neural networks. J Urol. 160:1998;430-436.
8. Han M., Snow P.B., Brandt J.M., et al. Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. Cancer. 91:2001;1661-1666.
9. Epstein J.I., Pound C.R., Partin A.W., et al. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol. 160:1998;97-101.
10. Chan T.Y., Partin A.W., Walsh P.C., et al. The prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 56:2000;823-827.
11. Epstein J.I., Partin A.W., Sauvageot J., et al. Prediction of progression following radical prostatectomy a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 20:1996;286-292.
12. Blute M.L., Bergstralh E.J., Iocca A., et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 165:2001;119-125.
13. Han M., Pound C.R., Potter S.R., et al. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins therapeutic implications. J Urol. 165:2001;864-866.
14. Khan M.A., Han M., Partin A.W., et al. Long-term cancer control of radical prostatectomy in men younger than 50 years of age update 2003. Urology. 62:2003;86-91.
15. D'Amico A.V., Renshaw A.A., Arsenault L., et al. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys. 45:1999;841-846.
16. Khan M.A., Partin A.W. Management of high-risk populations with locally advanced prostate cancer. Oncologist. 8:2003;259-269.